1. Health Utility Elicitation

   • Lisa A. Prosser
   • Scott D. Grosse
   • Eve Wittenberg

   Editorial 11 October 2012 Pages: 83 - 86

2. Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective

   • Aurea Duran
   • Nishan Sengupta
   • Michael Lees

   Original Research Article 11 October 2012 Pages: 87 - 101

   

3. Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer

   • Robert I. Griffiths
   • Richard L. Barron
   • Gary H. Lyman

   Original Research Article 11 October 2012 Pages: 103 - 118

   

4. Incorporating Calibrated Model Parameters into Sensitivity Analyses

   • Douglas Taylor
   • Vivek Pawar
   • Milton C. Weinstein

   Short Communication 11 October 2012 Pages: 119 - 126

   

5. Why Not Real Economics?

   • F. Reed Johnson

   Commentary 11 October 2012 Pages: 127 - 131

6. Real Economics Needs to Reflect Real Decisions

   • Mark Sculpher
   • Karl Claxton

   Commentary 11 October 2012 Pages: 133 - 136

7. Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery

   • Michael Holmes
   • Christopher Carroll
   • Diana Papaioannou

   Review Article 11 October 2012 Pages: 137 - 146

8. Osteoporotic Fractures

   • Sangeeta Budhia
   • Yeshi Mikyas
   • Enkhe Badamgarav

   Review Article 11 October 2012 Pages: 147 - 170